Find Elvitegravir manufacturers, exporters & distributors on PharmaCompass

Jtk 303

Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

14 API Suppliers, 7 USDMF, 4 EU WC, 2 KDMF, 8 NDC API, 7 Listed Suppliers

14 API Suppliers
7 USDMF
4 EU WC
2 KDMF
8 NDC API
7 Listed Suppliers

INTERMEDIATES

1 Intermediates Suppliers

1 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

12 FDF Dossiers, 4 FDA Orange Book, 6 Europe, 2 Canada

12 FDF Dossiers
4 FDA Orange Book
6 Europe
2 Canada

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 150MG, TABLET;ORAL - 85MG, TABLET;ORAL - 150MG;150MG;200MG;300MG, TABLET;ORAL - 150MG;150MG;200MG;EQ 10MG BASE

drugProductComposition
TABLET;ORAL - 150MG
TABLET;ORAL - 85MG
TABLET;ORAL - 150MG;150MG;200MG;300MG
TABLET;ORAL - 150MG;150MG;200MG;EQ 10MG BASE

RELATED EXCIPIENT COMPANIES

1 SPI Pharma, 2 Seqens, 3 DKSH, 1 Jai Radhe Sales, 9 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 3 Actylis, 1 Aeon Procare, 5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 14 BASF, 5 Corel Pharma Chem, 5 DFE Pharma, 1 Finar, 7 Gangwal Chemicals, 3 Ideal Cures Pvt Ltd, 1 Ingredion Pharma Solutions, 20 Kerry, 9 Microlex e.U, 2 Nomisma Healthcare, 1 Novo Excipients, 1 Pharmatrans-Sanaq, 4 Pluviaendo, 3 Prachin Chemical, 10 Roquette, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 11 Sigachi Industries, 3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

42 Fillers, Diluents & Binders, 22 Coating Systems & Additives, 20 Direct Compression, 16 Lubricants & Glidants, 15 Thickeners and Stabilizers, 15 Disintegrants & Superdisintegrants, 14 Controlled & Modified Release, 14 Granulation, 11 Co-Processed Excipients, 10 Topical, 5 Parenteral, 5 Film Formers & Plasticizers, 5 Taste Masking, 4 Solubilizers, 3 Emulsifying Agents, 2 Chewable & Orodispersible Aids, 2 API Stability Enhancers, 2 Coloring Agents, 2 Rheology Modifiers, 1 Surfactant & Foaming Agents

DIGITAL CONTENT

4 DATA COMPILATION #PharmaFlow, 16 NEWS #PharmaBuzz

media
4 DATA COMPILATION #PharmaFlow
16 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

4 Finished Drug Prices, 13 Annual Reports

globalSalesInformation
4 Finished Drug Prices
13 Annual Reports

MARKET PLACE

1 APIs

marketPlace
1 APIs

PATENTS & EXCLUSIVITIES

50 US Patents, 6 Health Canada Patents

patents
50 US Patents
6 Health Canada Patents

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

1INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

23,892

Finished Drug Prices

130 RELATED EXCIPIENT COMPANIES

210EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 697761-98-1, Gs-9137, Jtk-303, Vitekta, Gs 9137, Elvitegravir (gs-9137)

Molecular Formula

C₂₃H₂₃ClFNO₅

Molecular Weight

447.9 g/mol

InChI Key

JUZYLCPPVHEVSV-LJQANCHMSA-N

FDA UNII

4GDQ854U53

Elvitegravir is a modified quinolone antibiotic with activity against human immunodeficiency virus 1. Elvitegravir is an inhibitor of viral integrase and retains activity against integrase mutants that are resistant to Raltegravir.

Elvitegravir is a Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor. The mechanism of action of elvitegravir is as a HIV Integrase Inhibitor, and Cytochrome P450 2C9 Inducer.

1 2D Structure

Elvitegravir

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

6-[(3-chloro-2-fluorophenyl)methyl]-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxoquinoline-3-carboxylic acid

2.1.2 InChI

InChI=1S/C23H23ClFNO5/c1-12(2)19(11-27)26-10-16(23(29)30)22(28)15-8-14(20(31-3)9-18(15)26)7-13-5-4-6-17(24)21(13)25/h4-6,8-10,12,19,27H,7,11H2,1-3H3,(H,29,30)/t19-/m1/s1

2.1.3 InChI Key

JUZYLCPPVHEVSV-LJQANCHMSA-N

2.1.4 Canonical SMILES

CC(C)C(CO)N1C=C(C(=O)C2=C1C=C(C(=C2)CC3=C(C(=CC=C3)Cl)F)OC)C(=O)O

2.1.5 Isomeric SMILES

CC(C)[C@@H](CO)N1C=C(C(=O)C2=C1C=C(C(=C2)CC3=C(C(=CC=C3)Cl)F)OC)C(=O)O

2.2 Other Identifiers

2.2.1 UNII

4GDQ854U53

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Gs 9137

2. Gs-9137

3. Gs9137

4. Jtk 303

5. Jtk-303

6. Jtk303

7. Vitekta

2.3.2 Depositor-Supplied Synonyms

1. 697761-98-1

2. Gs-9137

3. Jtk-303

4. Vitekta

5. Gs 9137

6. Elvitegravir (gs-9137)

7. Evg

8. Unii-4gdq854u53

9. (s)-6-(3-chloro-2-fluorobenzyl)-1-(1-hydroxy-3-methylbutan-2-yl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid

10. 6-(3-chloro-2-fluorobenzyl)-1-[1(s)-(hydroxymethyl)-2-methylpropyl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid

11. Chebi:72289

12. 6-[(3-chloro-2-fluorophenyl)methyl]-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxoquinoline-3-carboxylic Acid

13. Chembl204656

14. 4gdq854u53

15. D06677

16. 6-(3-chloro-2-fluorobenzyl)-1-((2s)-1-hydroxy-3-methylbutan-2-yl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid

17. 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid

18. Jtk 303

19. 3-quinolinecarboxylic Acid, 6-((3-chloro-2-fluorophenyl)methyl)-1,4-dihydro-1-((1s)-1-(hydroxymethyl)-2-methylpropyl)-7-methoxy-4-oxo-

20. 6-(3-chloro-2-fluorobenzyl)-1-[(1s)-1-(hydroxymethyl)-2-methylpropyl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid

21. Jtk303

22. Elvitegravir [usan]

23. Gs9137

24. Elvitegravir [usan:inn]

25. Elvitegravirum

26. 6-(3-chloro-2-fluorobenzyl)-1-((1s)-1-(hydroxymethyl)-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid

27. 6-[(3-chloro-2-fluoro-phenyl)methyl]-1-[(1s)-1-(hydroxymethyl)-2-methyl-propyl]-7-methoxy-4-oxo-quinoline-3-carboxylic Acid

28. Elv

29. Vitekta (tn)

30. Elvitegravir [mi]

31. Elvitegravir (jan/usan)

32. Elvitegravir [inn]

33. Elvitegravir [jan]

34. Elvitegravir (jtk-303)

35. Elvitegravir [vandf]

36. Elvitegravir [mart.]

37. Mls006011136

38. Elvitegravir [who-dd]

39. Schembl726252

40. Gtpl11574

41. Bcpp000242

42. Dtxsid101021650

43. Elvitegravir [orange Book]

44. Ex-a1542

45. Bdbm50183273

46. Mfcd11846134

47. S2001

48. Vitekta Component Elvitegravir

49. Zinc13682481

50. Elvitegravir; Gs9137; Jtk 303

51. Stribild Component Elvitegravir

52. Akos025396642

53. Bcp9000642

54. Ccg-269208

55. Compound 2 [pmid: 18281931]

56. Cs-0439

57. Db09101

58. Elvitegravir (gs-9137, Jtk-303)

59. Elvitegravir Component Of Genvoya

60. Elvitegravir Component Of Vitekta

61. Elvitegravir Component Of Stribild

62. Ncgc00346565-01

63. Ncgc00346565-04

64. Ncgc00346565-08

65. Ac-29947

66. As-16986

67. Hy-14740

68. Smr004702914

69. Elvitegravir 100 Microg/ml In Acetonitrile

70. A4070

71. Sw219721-1

72. Ec-000.2332

73. Ab01274749-01

74. Ab01274749_02

75. J-518006

76. Q2740966

77. Brd-k54472332-001-01-8

78. 3-quinolinecarboxylic Acid, 6-[(3-chloro-2-fluorophenyl)methyl]-1,4-dihydro-1-[(1s)-1-isopropyl-2-hydroxyethyl]-7-methoxy-4-oxo-

79. 6-(3-chloro-2-fluorobenzyl)-1-[(s)-1-hydroxymethyl-2-methylpropyl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid

2.4 Create Date

2005-10-07

3 Chemical and Physical Properties

Molecular Formula	C₂₃H₂₃ClFNO₅
Molecular Weight	447.9 g/mol
XLogP3	5.3
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	7
Exact Mass	447.1248787 g/mol
Monoisotopic Mass	447.1248787 g/mol
Topological Polar Surface Area	87.1 Å²
Heavy Atom Count	31
Formal Charge	0
Complexity	702
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Elvitegravir in combination with an HIV protease inhibitor coadministered with ritonavir and with other antiretroviral drug(s) is indicated for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults.

FDA Label

Vitekta co-administered with a ritonavir-boosted protease inhibitor and with other antiretroviral agents, is indicated for the treatment of human-immunodeficiency-virus-1 (HIV-1) infection in adults who are infected with HIV-1 without known mutations associated with resistance to elvitegravir.

5 Pharmacology and Biochemistry

5.1 MeSH Pharmacological Classification

Anti-HIV Agents

Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)

Anti-Retroviral Agents

Agents used to treat RETROVIRIDAE INFECTIONS. (See all compounds classified as Anti-Retroviral Agents.)

Integrase Inhibitors

Compounds which inhibit or antagonize biosynthesis or actions of integrase. (See all compounds classified as Integrase Inhibitors.)

5.2 FDA Pharmacological Classification

5.2.1 Active Moiety

ELVITEGRAVIR

5.2.2 FDA UNII

4GDQ854U53

5.2.3 Pharmacological Classes

Mechanisms of Action [MoA] - Cytochrome P450 2C9 Inducers

5.3 ATC Code

J05AX11

J - Antiinfectives for systemic use

J05 - Antivirals for systemic use

J05A - Direct acting antivirals

J05AJ - Integrase inhibitors

J05AJ02 - Elvitegravir

5.4 Absorption, Distribution and Excretion

Absorption

Following oral administration of elvitegravir and ritonavir with food, in HIV-1 infected subjects, peak elvitegravir plasma concentrations were observed approximately 4 hours post-dose.

Route of Elimination

Following oral administration of [14C]elvitegravir/ritonavir, 94.8% of the dose was recovered in feces, while 6.7% was recovered in urine as metabolites.

5.5 Metabolism/Metabolites

Elvitegravir undergoes primarily oxidative metabolism via CYP3A, and is secondarily glucuronidated via UGT1A1/3 enzymes. Metabolites are found in the plasma at very low concentrations, displayed considerably lower anti-HIV activity, and did not contribute to the overall antiviral activity of elvitegravir.

5.6 Biological Half-Life

The median terminal plasma half-life following administration of elvitegravir and ritonavir was approximately 8.7 hours.

5.7 Mechanism of Action

Elvitegravir is an HIV-1 integrase strand transfer inhibitor (INSTI). Integrase is an HIV-1 encoded enzyme that is required for viral replication. Inhibition of integrase prevents the integration of HIV-1 DNA into host genomic DNA, blocking the formation of the HIV-1 provirus and propagation of the viral infection. Elvitegravir does not inhibit human topoisomerases I or II.

API SUPPLIERS